Type 2 Diabetes

Type 2 diabetes (T2D) is a metabolic disease affecting approximately 537 million adults worldwide, with numbers projected to reach 783 million by 2045. The condition develops when the body becomes resistant to insulin's effects and eventually can't produce enough insulin to overcome this resistance. Insulin is the hormone that allows cells to absorb glucose (sugar) from the bloodstream for energy. In T2D, cells throughout the body—particularly in muscle, liver, and fat tissue—stop responding normally to insulin signals, requiring increasingly higher insulin levels to move glucose into cells. The pancreas compensates initially by producing more insulin, but over time, the insulin-producing beta cells become exhausted and can't keep up with demand, causing blood glucose levels to rise. Unlike type 1 diabetes which is autoimmune and typically begins in childhood, type 2 usually develops gradually in adults, though increasingly affecting younger people and even children. Risk factors include excess weight (particularly abdominal fat), physical inactivity, genetic susceptibility (it runs strongly in families), age, ethnicity (some populations have substantially higher risk), previous gestational diabetes, and metabolic conditions. The disease involves complex interactions between genetics, lifestyle, inflammation, fat tissue dysfunction, liver glucose overproduction, and incretin hormone deficiency (gut hormones that regulate insulin and appetite). Early stages often cause no symptoms, so millions of people have undiagnosed diabetes discovered only through screening or when complications develop. Symptoms when present include increased thirst, frequent urination, blurred vision, slow-healing wounds, and fatigue.

Treatment begins with lifestyle modifications—weight loss (even 5-10% can significantly improve glucose control), regular physical activity, and dietary changes focusing on whole foods, controlled carbohydrate intake, and reduced processed foods. These interventions remain foundational throughout treatment. Metformin, an oral medication that reduces liver glucose production and improves insulin sensitivity, is typically the first medication prescribed and remains central to treatment for decades. The treatment landscape has expanded dramatically in recent years with multiple medication classes offering different mechanisms. GLP-1 receptor agonists (including semaglutide, dulaglutide, liraglutide) given by weekly or daily injection mimic gut hormones that stimulate insulin release, suppress appetite, and promote substantial weight loss—some people achieve glucose normalization with these drugs. SGLT2 inhibitors (like empagliflozin, dapagliflozin) work by causing kidneys to excrete excess glucose in urine and have cardiovascular and kidney protective benefits beyond glucose lowering. DPP-4 inhibitors block breakdown of natural incretin hormones. Older medication classes including sulfonylureas and thiazolidinediones remain useful in certain situations. For people who don't achieve glucose targets with oral medications and injectables, insulin therapy becomes necessary, ranging from once-daily long-acting insulin to multiple daily injections mimicking natural insulin patterns. Regular monitoring for complications—eye disease, kidney disease, nerve damage, cardiovascular disease, and foot problems—is essential, with early detection and treatment preventing or delaying serious outcomes. Many people with T2D maintain good glucose control and avoid complications through proper management.

Type 2 diabetes is progressive—even with treatment, beta cell function typically declines over time, requiring medication intensification and often eventual insulin therapy. Many people struggle to achieve and maintain target glucose levels despite multiple medications, leaving them at risk for complications. Hypoglycemia (dangerously low blood sugar), while less common than in type 1 diabetes, occurs with certain medications particularly insulin and sulfonylureas, creating fear and limiting aggressive glucose control. Cardiovascular disease remains the leading cause of death in people with T2D, and while newer medications offer cardiovascular protection, heart attacks, strokes, and heart failure rates remain elevated compared to people without diabetes. Weight management is challenging—many diabetes medications cause weight gain (including insulin and sulfonylureas), conflicting with the weight loss that would improve insulin sensitivity, though newer GLP-1 and SGLT2 medications help with weight. Medication side effects affect adherence—GLP-1 agonists cause nausea and gastrointestinal symptoms that lead some people to discontinue them, SGLT2 inhibitors increase urinary tract and genital infections, and various medications have other tolerability issues. Cost and access barriers prevent many people worldwide from obtaining necessary medications, monitoring supplies, and regular healthcare, with insulin access particularly problematic in resource-limited settings. Better ways to predict who will progress rapidly versus slowly would enable more personalized treatment intensity. Nothing currently available reverses insulin resistance or regenerates exhausted beta cells, meaning treatments manage rather than cure the underlying problem.

Tirzepatide, a dual GLP-1/GIP receptor agonist already approved for T2D and obesity, demonstrated superior glucose lowering and weight loss compared to single-mechanism GLP-1 drugs and is expanding globally. Triple agonists activating GLP-1, GIP, and glucagon receptors (including retatrutide) are in Phase 3 trials, showing even greater metabolic effects with substantial weight loss and glucose improvements. Oral GLP-1 receptor agonists eliminating injection requirements are advancing—oral semaglutide is already available, and improved formulations with better absorption and convenience are in trials. Novel insulin formulations including once-weekly insulins are in advanced testing, potentially reducing injection frequency from daily to weekly dosing. Glucose-responsive insulins that automatically activate when blood sugar rises and deactivate when it falls—essentially "smart" insulins—are in clinical trials, potentially reducing hypoglycemia risk. Combination medications pairing complementary mechanisms in single pills or injections are being developed to simplify regimens and improve adherence. SGLT1/SGLT2 dual inhibitors blocking glucose absorption in both the gut and kidneys are in trials. Drugs targeting novel mechanisms including glucagon receptor antagonists, FGF21 analogues affecting metabolism, and agents modulating fat tissue function are in Phase 2 and 3 testing. Cell-based therapies delivering insulin-producing cells or cells that improve insulin sensitivity are in early human trials.

Gene therapy approaches to enhance insulin production, improve insulin sensitivity in target tissues, or modify fat tissue metabolism are in early research. Scientists are developing stem cell-derived beta cells that could supplement failing pancreatic function, though challenges of immune rejection and glucose-responsive insulin release require solutions. CRISPR gene editing is being explored to modify genes affecting diabetes risk, insulin resistance, or beta cell function. Researchers are investigating the gut microbiome's role in T2D extensively, with evidence that intestinal bacteria influence glucose metabolism, inflammation, and drug responses—interventions including targeted probiotics, fecal microbiota transplants, and microbiome-modifying drugs are being explored. Artificial intelligence is being applied to predict who will develop diabetes years before onset (enabling preventive intervention), optimize treatment selection for individual patients, and discover new drug targets from massive datasets. Scientists are working to understand and reverse beta cell exhaustion, seeking drugs that could restore insulin production capacity. Novel drug targets are being identified through genetic studies, including pathways involving inflammation, mitochondrial function, cellular stress responses, and metabolic signaling. Nanotechnology-based drug delivery systems that could release medications in response to glucose levels or target them specifically to relevant tissues are in development. Bioelectronic medicine approaches using nerve stimulation to improve glucose metabolism and insulin sensitivity are being explored. Researchers are investigating why some people remain diabetes-free despite obesity and insulin resistance, seeking protective factors that could be therapeutically replicated. Scientists are developing better biomarkers beyond glucose measurements—markers of beta cell stress, insulin resistance in specific tissues, and inflammation—that could enable earlier intervention and treatment personalization. Vaccines targeting inflammatory pathways contributing to insulin resistance are in very early research. Cellular reprogramming techniques to convert other cell types into insulin-producing cells are being studied. Researchers are exploring whether reversing liver fat accumulation, visceral fat inflammation, or skeletal muscle mitochondrial dysfunction through targeted therapies could restore insulin sensitivity even without weight loss.